Alex Kentsis, MD, PhD - Publications

Memorial Sloan-Kettering Cancer Center, Rockville Centre, NY, United States 
Cancer biology, rational therapy, drug design

63 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Fiala EM, Ortiz MV, Kennedy JA, Glodzik D, Fleischut MH, Duffy KA, Hathaway ER, Heaton T, Gerstle JT, Steinherz P, Shukla N, McNeer N, Tkachuk K, Bouvier N, Cadoo K, ... ... Kentsis A, et al. 11p15.5 epimutations in children with Wilms tumor and hepatoblastoma detected in peripheral blood. Cancer. PMID 32320050 DOI: 10.1002/Cncr.32907  0.739
2019 Wan L, Chong S, Xuan F, Liang A, Cui X, Gates L, Carroll TS, Li Y, Feng L, Chen G, Wang SP, Ortiz MV, Daley SK, Wang X, Xuan H, ... Kentsis A, et al. Impaired cell fate through gain-of-function mutations in a chromatin reader. Nature. PMID 31853060 DOI: 10.1038/S41586-019-1842-7  0.375
2019 Ortiz MV, Ahmed S, Burns M, Henssen AG, Hollmann TJ, MacArthur I, Gunasekera S, Gaewsky L, Bradwin G, Ryan J, Letai A, He Y, Naranjo A, Chi YY, LaQuaglia M, ... ... Kentsis A, et al. Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumor. Jci Insight. 4. PMID 31391345 DOI: 10.1172/Jci.Insight.127098  0.324
2019 Sher F, Hossain M, Seruggia D, Schoonenberg VAC, Yao Q, Cifani P, Dassama LMK, Cole MA, Ren C, Vinjamur DS, Macias-Trevino C, Luk K, McGuckin C, Schupp PG, Canver MC, ... ... Kentsis A, et al. Rational targeting of a NuRD subcomplex guided by comprehensive in situ mutagenesis. Nature Genetics. PMID 31253978 DOI: 10.1038/S41588-019-0453-4  0.343
2019 MacArthur IC, Bei Y, Dorado García H, Ortiz MV, Toedling J, Klironomos F, Rolff J, Eggert A, Schulte JH, Kentsis A, Henssen AG. Prohibitin promotes de-differentiation and is a potential therapeutic target in neuroblastoma. Jci Insight. 5. PMID 30998507 DOI: 10.1172/Jci.Insight.127130  0.333
2019 McNeer NA, Philip J, Geiger H, Ries RE, Lavallée VP, Walsh M, Shah M, Arora K, Emde AK, Robine N, Alonzo TA, Kolb EA, Gamis AS, Smith M, Gerhard DS, ... ... Kentsis A, et al. Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. Leukemia. PMID 30760869 DOI: 10.1038/S41375-019-0402-3  0.76
2019 McNeer N, Philip J, Geiger H, Ries RE, Lavallee V, Walsh M, Shah M, Arora K, Emde A, Robine N, Alonzo TA, Kolb EA, Gamis AS, Smith M, Gerhard DS, ... ... Kentsis A, et al. Abstract 2870: Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-2870  0.741
2018 Henssen AG, Kentsis A. Emerging functions of DNA transposases and oncogenic mutators in childhood cancer development. Jci Insight. 3. PMID 30333322 DOI: 10.1172/Jci.Insight.123172  0.348
2018 Cifani P, Dhabaria A, Chen Z, Yoshimi A, Kawaler E, Abdel-Wahab O, Poirier JT, Kentsis A. ProteomeGenerator: A framework for comprehensive proteomics based on de novo transcriptome assembly and high-accuracy peptide mass spectral matching. Journal of Proteome Research. PMID 30295032 DOI: 10.1021/Acs.Jproteome.8B00295  0.312
2018 Johnson DC, Taabazuing CY, Okondo MC, Chui AJ, Rao SD, Brown FC, Reed C, Peguero E, de Stanchina E, Kentsis A, Bachovchin DA. DPP8/DPP9 inhibitor-induced pyroptosis for treatment of acute myeloid leukemia. Nature Medicine. PMID 29967349 DOI: 10.1038/S41591-018-0082-Y  0.347
2018 Hoshii T, Cifani P, Feng Z, Huang CH, Koche R, Chen CW, Delaney CD, Lowe SW, Kentsis A, Armstrong SA. A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response. Cell. 172: 1007-1021.e17. PMID 29474905 DOI: 10.1016/J.Cell.2018.01.032  0.317
2018 Gutierrez A, Kentsis A. Acute myeloid/T-lymphoblastic leukaemia (AMTL): a distinct category of acute leukaemias with common pathogenesis in need of improved therapy. British Journal of Haematology. PMID 29441563 DOI: 10.1111/Bjh.15129  0.319
2018 Brown FC, Still E, Koche RP, Yim CY, Takao S, Cifani P, Reed C, Gunasekera S, Ficarro SB, Romanienko P, Mark W, McCarthy C, de Stanchina E, Gonen M, Seshan V, ... ... Kentsis A, et al. MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia. Cancer Discovery. PMID 29431698 DOI: 10.1158/2159-8290.Cd-17-1271  0.361
2018 Ramaswamy K, Forbes L, Minuesa G, Gindin T, Brown F, Kharas MG, Krivtsov AV, Armstrong SA, Still E, de Stanchina E, Knoechel B, Koche R, Kentsis A. Peptidomimetic blockade of MYB in acute myeloid leukemia. Nature Communications. 9: 110. PMID 29317678 DOI: 10.1038/s41467-017-02618-6  0.743
2018 Takao S, Koche R, Cifani P, Ser Z, Kentsis A. Functional Profiling of Patient AML Stem Cells Reveals Mechanisms of Epigenetic Plasticity Controlling Therapy Resistance Blood. 132: 1318-1318. DOI: 10.1182/Blood-2018-99-114433  0.371
2018 Cifani P, Dogan A, Solit DB, Kentsis A. Abstract 5650: Functional proteomics for precise cancer diagnosis and therapy using the MSK Quantitative Cancer Proteomics Atlas Cancer Research. 78: 5650-5650. DOI: 10.1158/1538-7445.Am2018-5650  0.381
2017 Henssen AG, Reed C, Jiang E, Garcia HD, von Stebut J, MacArthur IC, Hundsdoerfer P, Kim JH, de Stanchina E, Kuwahara Y, Hosoi H, Ganem NJ, Dela Cruz F, Kung AL, Schulte JH, ... ... Kentsis A, et al. Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors. Science Translational Medicine. 9. PMID 29093183 DOI: 10.1126/Scitranslmed.Aam9078  0.355
2017 Henssen AG, Koche R, Zhuang J, Jiang E, Reed C, Eisenberg A, Still E, MacArthur IC, Rodríguez-Fos E, Gonzalez S, Puiggròs M, Blackford AN, Mason CE, de Stanchina E, Gönen M, ... ... Kentsis A, et al. PGBD5 promotes site-specific oncogenic mutations in human tumors. Nature Genetics. PMID 28504702 DOI: 10.1038/Ng.3866  0.349
2017 Ortiz MV, Magnan H, Slotkin EK, Ambati SR, Chou AJ, Wexler LH, Meyers PA, Walsh MF, Heaton T, Girardi LN, Wolden SL, Price AP, Kennedy JA, Zehir A, Hameed M, ... ... Kentsis A, et al. Intracardiac Low-grade Sarcoma Following Treatment for Ewing Sarcoma. Journal of Pediatric Hematology/Oncology. PMID 28060130 DOI: 10.1097/Mph.0000000000000754  0.322
2017 Ortiz MV, Burns M, Eisenberg A, Ahmed S, Gaewsky L, Bradwin G, Cifani P, Henssen A, Macarthur I, LaQuaglia M, Letai A, Naranjo A, Gadd S, Chi Y, Dome J, ... ... Kentsis A, et al. Abstract 708: Prohibitin is a prognostic marker of treatment failure and therapeutic target to block chemotherapy resistance in Wilms tumor Cancer Research. 77: 708-708. DOI: 10.1158/1538-7445.Am2017-708  0.356
2016 Brown FC, Cifani P, Drill E, He J, Still E, Zhong S, Balasubramanian S, Pavlick D, Yilmazel B, Knapp KM, Alonzo TA, Meshinchi S, Stone RM, Kornblau SM, Marcucci G, ... ... Kentsis A, et al. Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia. British Journal of Haematology. PMID 27766616 DOI: 10.1111/Bjh.14413  0.357
2016 Mathias MD, Chou AJ, Meyers P, Shukla N, Hameed M, Agaram N, Wang L, Berger MF, Walsh M, Kentsis A. Osteosarcoma With Apparent Ewing Sarcoma Gene Rearrangement. Journal of Pediatric Hematology/Oncology. 38: e166-e168. PMID 27352193 DOI: 10.1097/Mph.0000000000000553  0.329
2016 Brown FC, Still E, Cifani P, Reed C, Ficarro S, He J, Koche R, Bhola P, Romanienko P, Mark W, Krivtsov AV, Letai A, Gray N, Marto J, Armstrong SA, ... Kentsis A, et al. Aberrant Phosphorylation of MEF2C Is Dispensable for Hematopoiesis, and Induces Chemotherapy Resistance and Susceptibility to MARK Kinase Inhibition Therapy in Acute Myeloid Leukemia Blood. 128: 436-436. DOI: 10.1182/Blood.V128.22.436.436  0.384
2016 Hoshii T, Cifani P, Nakadai T, Feng Z, Huang C, Koche R, Delaney CD, Chen CD, Lowe SW, Roeder R, Kentsis A, Armstrong SA. Non-Catalytic Role of SETD1A Regulates DNA Repair in Leukemia Blood. 128: 434-434. DOI: 10.1182/Blood.V128.22.434.434  0.349
2016 Wang M, Ser Z, Rao S, Fahl S, Zhang Y, Peri S, Kentsis A, Wiest DL. Ribosomal Protein Rpl22 Regulates Development and Transformation Via Altering RNA Processing Blood. 128: 3878-3878. DOI: 10.1182/Blood.V128.22.3878.3878  0.352
2016 Kobos R, He J, Steinherz PG, Curran KJ, Renaud TM, Forlenza C, Boulad F, Prockop S, Knapp KM, Walsh M, Roshal M, Wang L, Papaemmanuil E, Dogan A, Zhong S, ... ... Kentsis A, et al. Comprehensive Genomic Profiling for Improved Diagnosis and Therapy of Pediatric Acute Leukemias Blood. 128: 1605-1605. DOI: 10.1182/Blood.V128.22.1605.1605  0.34
2015 Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Kentsis A, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB. High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Journal of Hematology & Oncology. 8: 115. PMID 26487643 DOI: 10.1182/Blood.V126.23.2570.2570  0.316
2015 Etchin J, Montero J, Berezovskaya A, Le BT, Kentsis A, Christie AL, Conway AS, Chen WC, Reed C, Mansour MR, Ng CE, Adamia S, Rodig SJ, Galinsky IA, Stone RM, et al. Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-Initiating cells engrafted into immunosuppressed NSG mice. Leukemia. PMID 26202935 DOI: 10.1038/Leu.2015.194  0.383
2015 Ramaswamy K, Spitzer B, Kentsis A. Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid Leukemia. Frontiers in Oncology. 5: 16. PMID 25699237 DOI: 10.3389/Fonc.2015.00016  0.384
2015 Mansour MR, Reed C, Eisenberg AR, Tseng JC, Twizere JC, Daakour S, Yoda A, Rodig SJ, Tal N, Shochat C, Berezovskaya A, DeAngelo DJ, Sallan SE, Weinstock DM, Izraeli S, ... ... Kentsis A, et al. Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia. British Journal of Haematology. 168: 230-8. PMID 25256574 DOI: 10.1111/Bjh.13115  0.376
2015 Brown F, Still E, Cifani P, Ficarro S, Pouliot G, Drill E, Gonen M, He J, Balasubramanian S, Zhong S, Pavlick D, Yilmazel B, Krivtsov AV, Alonzo TA, Meshinchi S, ... ... Kentsis A, et al. Genomic and Proteomic Analysis of Primary Chemoresistance and Induction Failure in Acute Myeloid Leukemia Blood. 126: 88-88. DOI: 10.1182/Blood.V126.23.88.88  0.403
2015 Cifani P, Shakiba M, Brown F, Dhabaria A, Bauer DE, Kentsis A. Functional Proteomics of Regulatory and Epigenetic Signaling in Normal and Malignant Hematopoiesis Blood. 126: 4972-4972. DOI: 10.1182/Blood.V126.23.4972.4972  0.353
2015 Etchin J, Le BT, Berezovskaya A, Conway AS, Chen WC, Kentsis A, Mansour MR, Stone RM, Galinsky IA, DeAngelo DJ, McCauley D, Kauffman M, Shacham S, Wang JC, Kung AL, et al. Abstract 4445: Selective inhibitor of nuclear exporter CRM1/XPO1, Selinexor (KPT-330), exhibits remarkable activity against AML leukemia-initiating cells while sparing normal hematopoietic cells Cancer Research. 75: 4445-4445. DOI: 10.1158/1538-7445.Am2015-4445  0.715
2015 Henssen A, Eisenberg A, Jiang E, Henaff E, Koche R, Burns M, Carson JR, Nanjangud G, Still E, Gandara J, Cifani P, Dhabaria A, Huang X, Stanchina Ed, Mullen E, ... ... Kentsis A, et al. Abstract 1103: Human tumorigenesis induced by endogenous DNA transposase Cancer Research. 75: 1103-1103. DOI: 10.1158/1538-7445.Am2015-1103  0.366
2014 Gutierrez A, Pan L, Groen RWJ, Baleydier F, Kentsis A, Marineau J, Grebliunaite R, Kozakewich E, Reed C, Pflumio F, Poglio S, Uzan B, Clemons P, VerPlank L, An F, et al. Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia Journal of Clinical Investigation. 124: 644-655. PMID 24401270 DOI: 10.1172/Jci65093  0.341
2014 Etchin J, Le BT, Kentsis A, Mansour MR, Berezovskaya A, Stone RM, Galinsky I, DeAngelo DJ, McCauley D, Kauffman M, Shacham S, Wang JCY, Kung AL, Look AT. ­Selective Inhibitor of Nuclear Export (SINE), Selinexor (KPT-330), Shows Remarkable Activity Against AML Leukemia-Initiating Cells Blood. 124: 995-995. DOI: 10.1182/Blood.V124.21.995.995  0.377
2014 Gutierrez A, Pan L, Groen R, Baleydier F, Kentsis A, Marineau J, Grebliunaite R, Kozakewich E, Reed C, Pflumio F, Poglio S, Uzan B, Clemons P, Verplank L, An F, et al. Abstract IA8: A new class of drugs active in T-ALL is revealed in a zebrafish screen Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Modorg-Ia8  0.343
2013 Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, Christie AL, McCauley D, Rodig SJ, Kauffman M, Shacham S, Stone R, Letai A, Kung AL, Thomas Look A. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. British Journal of Haematology. 161: 117-27. PMID 23373539 DOI: 10.1111/Bjh.12231  0.367
2013 Etchin J, Sun Q, Kentsis A, Farmer A, Zhang ZC, Sanda T, Mansour MR, Barcelo C, McCauley D, Kauffman M, Shacham S, Christie AL, Kung AL, Rodig SJ, Chook YM, et al. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia. 27: 66-74. PMID 22847027 DOI: 10.1038/Leu.2012.219  0.366
2013 Etchin J, Le BT, Kentsis A, Stone RM, McCauley D, Kauffman M, Shacham S, Wang JCY, Kung AL, Look AT. Novel Inhibitors Of CRM1/XPO1 Nuclear Exporter Exhibit Striking Activity Against AML “primagrafts,” Including AML Leukemia Initiating Cells, While Sparing Normal Hematopoietic Cells Blood. 122: 3932-3932. DOI: 10.1182/Blood.V122.21.3932.3932  0.396
2013 Reed C, Eisenberg A, Tseng J, Yoda A, Rodig SJ, DeAngelo DJ, Sallan SE, Weinstock DM, Izraeli S, Kung AL, Kentsis A, Look T. Targeting Oncogenic Interleukein-7 Receptor Signaling With N-Acetylcysteine In T-Cell Acute Lymphoblastic Leukemia Blood. 122: 2535-2535. DOI: 10.1182/Blood.V122.21.2535.2535  0.704
2012 Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E, Christie A, Valk PJ, Delwel R, Ngo V, Kutok JL, Dahlberg SE, Moreau LA, Byers RJ, Christensen JG, et al. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nature Medicine. 18: 1118-22. PMID 22683780 DOI: 10.1038/Nm.2819  0.376
2012 Etchin J, Kentsis A, Sanda T, Kung AL, Stone RM, McCauley D, Kauffman M, Shacham S, Look AT. Evaluation of KPT-SINE (Selective Inhibitors of CRM1-Mediated Nuclear Export) in AML and T-ALL. Journal of Clinical Oncology. 30: e13586-e13586. DOI: 10.1200/Jco.2012.30.15_Suppl.E13586  0.375
2012 Gutierrez A, Kentsis A, Pan L, Baleydier F, Marineau J, Grebliunaite R, Kozakewich E, Reed C, Pflumio F, Poglio S, Uzan B, Clemons PA, VerPlank L, An WF, Burbank J, et al. Phenothiazines Induce Apoptosis in T-Cell Acute Lymphoblastic Leukemia by Activating the Phosphatase Activity of the PP2A Tumor Suppressor Blood. 120: 3558-3558. DOI: 10.1182/Blood.V120.21.3558.3558  0.361
2011 Gutierrez A, Kentsis A, Sanda T, Holmfeldt L, Chen SC, Zhang J, Protopopov A, Chin L, Dahlberg SE, Neuberg DS, Silverman LB, Winter SS, Hunger SP, Sallan SE, Zha S, et al. The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia. Blood. 118: 4169-73. PMID 21878675 DOI: 10.1182/Blood-2010-11-318873  0.336
2011 Etchin J, Kentsis A, Sanda T, Kung AL, Stone RM, McCauley D, Kauffman M, Shacham S, Look T. KPT-SINE, a Potent, Small Molecule Inhibitor of CRM1-Dependent Nuclear-Cytoplasmic Shuttling, with Potent Activity Against T-ALL and AML Blood. 118: 2622-2622. DOI: 10.1182/Blood.V118.21.2622.2622  0.702
2011 Kentsis A, Sanda T, Reed C, Rodig SJ, Tholouli E, Ngo V, Kutok JL, Dahlberg SE, Moreau LA, Vande Woude G, Christensen J, Byers R, Kung AL, Staudt LM, Look T. Combined Targeting of the MET and FGF Receptor Tyrosine Kinases Induces Sustained AML Cell Death by Preventing Compensatory Upregulation of HGF in Response to MET Kinase Inhibition Blood. 118: 1405-1405. DOI: 10.1182/Blood.V118.21.1405.1405  0.692
2010 Gutierrez A, Kentsis A, Sanda T, Etchin J, Protopopov A, Zhang J, Chin L, Silverman LB, Winter S, Hunger S, Sallan SE, Zha S, Alt F, Look AT. The BCL11B Tumor Suppressor Is Mutated In Human T-Cell Acute Lymphoblastic Leukemia Blood. 116: 4177-4177. DOI: 10.1182/Blood.V116.21.4177.4177  0.349
2010 Kentsis A, Sanda T, Ngo V, Rodig SJ, Kutok J, Tholouli E, Byers R, Woude GV, Kung AL, Staudt LM, Look AT. Aberrant Expression of Hepatocyte Growth Factor Induces Autocrine MET Activation Providing a Novel Therapeutic Target In Acute Myeloid Leukemia. Blood. 116: 1042-1042. DOI: 10.1182/Blood.V116.21.1042.1042  0.387
2009 Kentsis A, Monigatti F, Dorff K, Campagne F, Bachur R, Steen H. Urine proteomics for profiling of human disease using high accuracy mass spectrometry. Proteomics. Clinical Applications. 3: 1052-1061. PMID 21127740 DOI: 10.1002/Prca.200900008  0.301
2007 Kentsis A, Gindin T, Mezei M, Osman R. Calculation of the free energy and cooperativity of protein folding Plos One. 2. PMID 17505540 DOI: 10.1371/Journal.Pone.0000446  0.74
2005 Kentsis A, Mezei M, Osman R. Origin of the sequence-dependent polyproline II structure in unfolded peptides Proteins: Structure, Function and Genetics. 61: 769-776. PMID 16193481 DOI: 10.1002/Prot.20655  0.524
2005 Ulane CM, Kentsis A, Cruz CD, Parisien JP, Schneider KL, Horvath CM. Composition and assembly of STAT-targeting ubiquitin ligase complexes: paramyxovirus V protein carboxyl terminus is an oligomerization domain. Journal of Virology. 79: 10180-9. PMID 16051811 DOI: 10.1128/Jvi.79.16.10180-10189.2005  0.313
2005 Topisirovic I, Kentsis A, Perez JM, Guzman ML, Jordan CT, Borden KL. Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels. Molecular and Cellular Biology. 25: 1100-12. PMID 15657436 DOI: 10.1128/Mcb.25.3.1100-1112.2005  0.614
2005 Miller F, Kentsis A, Osman R, Pan ZQ. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL·hypoxia-inducible transcription factor-1α complex Journal of Biological Chemistry. 280: 7985-7996. PMID 15611064 DOI: 10.1074/Jbc.M413160200  0.505
2004 Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KLB. Ribavirin suppresses elF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap Proceedings of the National Academy of Sciences of the United States of America. 101: 18105-18110. PMID 15601771 DOI: 10.1073/Pnas.0406927102  0.343
2004 Kentsis A, Mezei M, Gindin T, Osman R. Unfolded State of Polyalanine Is a Segmented Polyproline II Helix Proteins: Structure, Function and Genetics. 55: 493-501. PMID 15103613 DOI: 10.1002/Prot.20051  0.738
2004 Pan ZQ, Kentsis A, Dias DC, Yamoah K, Wu K. Nedd8 on cullin: Building an expressway to protein destruction Oncogene. 23: 1985-1997. PMID 15021886 DOI: 10.1038/Sj.Onc.1207414  0.314
2003 Kentsis A, Mezei M, Osman R. MC-PHS: A Monte Carlo implementation of the primary hydration shell for protein folding and design Biophysical Journal. 84: 805-815. PMID 12547765 DOI: 10.1016/S0006-3495(03)74900-5  0.485
2001 Kentsis A, Dwyer EC, Perez JM, Sharma M, Chen A, Pan ZQ, Borden KLB. The RING domains of the promyelocytic leukemia protein PML and the arenaviral protein Z repress translation by directly inhibiting translation initiation factor eIF4E Journal of Molecular Biology. 312: 609-623. PMID 11575918 DOI: 10.1006/Jmbi.2001.5003  0.327
2000 Krantz BA, Moran LB, Kentsis A, Sosnick TR. D/H amide kinetic isotope effects reveal when hydrogen bonds form during protein folding. Nature Structural Biology. 7: 62-71. PMID 10625430 DOI: 10.1038/71265  0.696
1999 Moran LB, Schneider JP, Kentsis A, Reddy GA, Sosnick TR. Transition state heterogeneity in GCN4 coiled coil folding studied by using multisite mutations and crosslinking. Proceedings of the National Academy of Sciences of the United States of America. 96: 10699-704. PMID 10485889 DOI: 10.1073/Pnas.96.19.10699  0.565
1998 Kentsis A, Sosnick TR. Trifluoroethanol promotes helix formation by destabilizing backbone exposure: desolvation rather than native hydrogen bonding defines the kinetic pathway of dimeric coiled coil folding. Biochemistry. 37: 14613-22. PMID 9772190 DOI: 10.1021/Bi981641Y  0.549
Show low-probability matches.